Gilead Anti-Infectives Forum

This website is intended for healthcare professionals who are currently residing and practising in the United Kingdom and Ireland.

This is a promotional website designed, built and funded by Gilead Sciences Ltd.

I am a healthcare professional in the UK / Ireland I am a member of the public
By checking this box, you hereby confirm that you are a healthcare professional and that you reside and practise within the United Kingdom or Ireland
Please confirm that you have read and accepted our
Privacy policy and Terms of use
Continue

UK-AMB-1047  |  January 2024 © 2024 Gilead Sciences, Inc. All rights reserved

Gilead Sciences Ltd, 280 High Holborn, London, WC1V 7EE, Phone: 44 (0) 203 681 4500    |   UKMed.Info@gilead.com   |   ©2024 Gilead Sciences Ltd. All rights reserved

Indications

AmBisome®

(Liposomal amphotericin B) is indicated for the treatment of systemic fungal infections in adults and children (aged 1 month to 18 years old). For a full list of indications, please refer to the AmBisome® summary of product characteristics available here: UK | Ireland

Veklury®

Veklury® is indicated for the treatment of coronavirus disease 2019 (COVID-19) in adults and paediatric patients (at least 4 weeks of age and weighing at least 3 kg) with pneumonia requiring supplemental oxygen (low or high-flow oxygen or other non-invasive ventilation at start of treatment), and adults and paediatric patients (weighing at least 40 kg) who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19. For a full list of indications, please refer to the Veklury® summary of product characteristics available here: Great Britain | Northern Ireland and Republic of Ireland

About Gilead

At Gilead, we challenge what is possible in serious diseases, going beyond what has been done before. Our highly skilled teams are committed to improving care for people across the UK and Ireland.

Bringing forward innovative new treatments is a critical part of our work, but it is not the end of it. Our commitment is to look beyond our medicines: to listen, learn and find effective solutions in the areas that matter most. We believe in effective collaboration and partnership with healthcare systems and patient groups. We are especially proud of our efforts in this area, which have been recognised as some of the best in the industry. Gilead invests in supporting programmes that provide education, prevention and care for some of the most vulnerable communities.

Gilead website